RayKnowChina Research Map
Shortlist0

RecruitingStomach cancerPhase not stated

Registered title, quoted from ClinicalTrials.gov

Gastric Cancer Marker Detection and Its Kit Development

An open trial on stomach cancer, registered on ClinicalTrials.gov. Led by Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorSecond Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University温州医科大学附属第二医院WenzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT05010863, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 2

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (2 points)Hide the checklist
  1. Patients who are diagnosed with cancer after pathological diagnosis;

    Inclusion criterion 2

  2. Received major surgery within 90 days before the experiment;

    Exclusion criterion 5

    Received bone marrow transplantation 90 days before the experiment;

    Exclusion criterion 6

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; day-to-day activity level; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT05010863, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

patient

  • Age is greater than or equal to 18 years old (including 18 years old);
  • Patients who are diagnosed with cancer after pathological diagnosis;
  • Can provide enough tissue samples;
  • Have not received anti-tumor treatment in the past;
  • Comply with the principle of informed consent and sign the informed consent form.

healthy person:

  • Age is greater than or equal to 18 years old (including 18 years old);
  • No underlying disease;
  • Can provide enough tissue samples;
  • Comply with the principle of informed consent and sign the informed consent form.

Exclusion Criteria:

  • The tumor foci cannot be clearly derived from a specific tumor type;
  • Those who have a history of other tumors, autoimmune diseases and allergies;
  • Previously received anti-tumor treatments such as surgery, chemotherapy, radiotherapy, molecular targeted therapy, immunotherapy, biological therapy or Chinese medicines with anti-cancer and anti-tumor effects in the instructions;
  • Participated in any clinical trial within 90 days before the experiment;
  • Received major surgery within 90 days before the experiment;
  • Received bone marrow transplantation 90 days before the experiment;
  • Subjects who may not be able to complete the study due to other reasons or who are determined by the investigator to be unsuitable to participate in this study.

Quoted from ClinicalTrials.gov, NCT05010863, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT05010863, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT05010863